Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 351

1.

Rationale for using serotonergic agents to treat irritable bowel syndrome.

Baker DE.

Am J Health Syst Pharm. 2005 Apr 1;62(7):700-11; quiz 712-3. Review.

PMID:
15790796
2.
3.

Role of serotonin in gastrointestinal motility and irritable bowel syndrome.

Sikander A, Rana SV, Prasad KK.

Clin Chim Acta. 2009 May;403(1-2):47-55. doi: 10.1016/j.cca.2009.01.028. Review.

PMID:
19361459
4.

Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.

De Ponti F, Tonini M.

Drugs. 2001;61(3):317-32. Review.

PMID:
11293643
5.

The brain-gut axis in irritable bowel syndrome--clinical aspects.

Mach T.

Med Sci Monit. 2004 Jun;10(6):RA125-31. Review.

PMID:
15173682
6.
7.

Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.

Lembo A, Weber HC, Farraye FA.

Drugs. 2003;63(18):1895-905. Review.

PMID:
12930162
8.

The role of serotonin in irritable bowel syndrome: implications for management.

Garvin B, Wiley JW.

Curr Gastroenterol Rep. 2008 Aug;10(4):363-8. Review.

PMID:
18627647
9.

[Role of serotonin in the pathophysiology of the irritable bowel syndrome].

Moskwa A, BoznaƄska P.

Wiad Lek. 2007;60(7-8):371-6. Review. Polish.

PMID:
18175558
10.

The spectrum of irritable bowel syndrome: A clinical review.

Gilkin RJ Jr.

Clin Ther. 2005 Nov;27(11):1696-709. Review.

PMID:
16368443
11.

Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.

Wagstaff AJ, Frampton JE, Croom KF.

Drugs. 2003;63(11):1101-20. Review.

PMID:
12749744
12.

Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome.

Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL.

Gastroenterology. 2004 Jun;126(7):1657-64.

PMID:
15188158
13.

Irritable bowel syndrome: new pharmaceutical approaches to treatment.

Farthing MJ.

Baillieres Best Pract Res Clin Gastroenterol. 1999 Oct;13(3):461-71. Review.

PMID:
10580922
14.

Psychotherapeutics and serotonin agonists and antagonists.

Mertz H.

J Clin Gastroenterol. 2005 May-Jun;39(5 Suppl 3):S247-50. Review.

PMID:
15798492
15.

Tegaserod for constipation-predominant irritable bowel syndrome.

Kale-Pradhan PB, Wilhelm SM.

Pharmacotherapy. 2007 Feb;27(2):267-77. Review.

PMID:
17253916
16.

Irritable bowel syndrome: update on pathogenesis and management.

Alaradi O, Barkin JS.

Med Princ Pract. 2002 Jan-Mar;11(1):2-17. Review.

PMID:
12116690
17.

The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.

McLaughlin J, Houghton LA.

Expert Opin Drug Saf. 2006 Mar;5(2):313-27. Review.

PMID:
16503751
18.

Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.

Chey WD, Cash BD.

Expert Opin Investig Drugs. 2005 Feb;14(2):185-93. Review.

PMID:
15757394
19.

Diagnostic and therapeutic strategies in the irritable bowel syndrome.

Cremonini F, Talley NJ.

Minerva Med. 2004 Oct;95(5):427-41. Review.

PMID:
15467518
20.

Review of tegaserod in the treatment of irritable bowel syndrome.

Patel S, Berrada D, Lembo A.

Expert Opin Pharmacother. 2004 Nov;5(11):2369-79. Review.

PMID:
15500384
Items per page

Supplemental Content

Support Center